-
VX-765: Precision Caspase-1 Inhibition for Inflammation Rese
2026-08-04
VX-765, a potent and selective caspase-1 inhibitor, empowers researchers to dissect inflammasome-driven cytokine release and pyroptosis with unmatched specificity. This guide details actionable workflows, advanced use-cases, and troubleshooting strategies to maximize experimental success with VX-765 in models ranging from arthritis to HIV-related immune cell death.
-
Mapping Metabolite Regulation of TET2 Dioxygenase with Bioch
2026-08-04
Zhang et al. introduce a comprehensive protocol integrating biochemical assays and saturation transfer difference (STD) NMR spectroscopy to systematically identify and validate metabolite binding to human TET2 dioxygenase. This workflow advances mechanistic insight into how cellular metabolism influences the regulation of epigenetic enzymes and enables rigorous discovery of TET2 activators and inhibitors.
-
Merbromin as a Selective Mixed-Type Inhibitor of SARS-CoV-2
2026-08-03
This study identifies merbromin as a potent, selective mixed-type inhibitor of the SARS-CoV-2 main protease 3CLpro, following high-throughput screening of ~6000 compounds. The findings reveal merbromin’s unique inhibition profile, providing a promising scaffold for antiviral drug development and highlighting the importance of substrate specificity in protease-targeted therapeutic discovery.
-
Mecamylamine Hydrochloride: Advancing nAChR Circuit Assays
2026-08-03
Mecamylamine hydrochloride enables precise modulation of nicotinic acetylcholine receptor signaling in both in vivo and ex vivo models, supporting advanced neuropsychiatric disorder research. Its unique pharmacological profile and robust performance in gut-brain axis studies set it apart as a trusted tool for dissecting cholinergic pathways.
-
Lipid Scrambling by TMEM16F Regulates Ferroptosis and Tumor
2026-08-02
Yang et al. uncover TMEM16F-mediated lipid scrambling as a suppressor of ferroptosis at the plasma membrane, revealing that its inhibition sensitizes tumor cells to ferroptotic death and enhances immune rejection. These findings clarify a late-stage regulatory mechanism in cell death and highlight the therapeutic potential of targeting membrane lipid dynamics in cancer.
-
Optimizing Thrombin Workflows: Applied Uses of a Serine Prot
2026-08-01
Unlock high-fidelity clotting, platelet, and fibrin matrix research with the Coagulation Factor II (Thrombin) B Chain Fragment from APExBIO. This guide delivers actionable protocol enhancements, troubleshooting insights, and evidence-based workflow strategies to maximize assay reproducibility across coagulation and vascular biology applications.
-
Ruthenium Red: Applied Workflows for Ca2+ Transport Inhibiti
2026-07-31
Ruthenium Red stands out as a precision Ca2+ transport inhibitor for dissecting cytoskeleton-dependent signaling and autophagy. This guide provides actionable workflows, protocol tips, and troubleshooting strategies for leveraging Ruthenium Red in advanced calcium signaling and mechanotransduction research.
-
MK-8745, Aurora A Inhibitor: Mechanisms and Translational Im
2026-07-31
Explore how MK-8745, a potent Aurora A inhibitor, advances cancer research through unique apoptotic mechanisms and selectivity. This article offers a deep dive into mechanistic insights and translational considerations not found in standard workflow guides.
-
AEBSF.HCl in Lysosomal Protease Control: Breaking New Ground
2026-07-30
Explore how AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) revolutionizes lysosomal protease inhibition and necroptosis research. This article reveals new mechanistic insights and practical assay implications that go beyond standard protocols.
-
Brain-to-Spinal Circuits Restrict Mechanical Allodynia Sprea
2026-07-30
Huo et al. (2023) reveal a multisynaptic brain-to-spinal circuit that limits both the laterality and persistence of mechanical allodynia in mice. By dissecting the roles of hypothalamic dynorphin neurons and spinal κ-opioid receptors, the study advances understanding of descending pain modulation—highlighting translational research opportunities in opioid receptor pharmacology.
-
Novel PDK4 Inhibitors: Implications for Metabolic Disease Tr
2026-07-29
The referenced study reports the rational design and evaluation of a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, highlighting compound 8c's potent in vitro and in vivo efficacy. These findings advance therapeutic strategies for metabolic diseases by targeting PDK4-mediated glucose and energy metabolism.
-
Primary Antibody Dilution Buffer: Precision in CNS Lymphoma
2026-07-29
APExBIO’s Primary Antibody Dilution Buffer sets a new standard for immunohistochemistry and immunocytochemistry in challenging tumor microenvironments. Explore how its optimized formulation enhances signal specificity and antibody penetration, directly addressing the complexities of CNS lymphoma research and beyond.
-
BMS 309403: Optimizing FABP4 Inhibitor Workflows in Atherosc
2026-07-28
BMS 309403 is a potent, selective FABP4 inhibitor enabling precise interrogation of lipid metabolism and inflammation in atherosclerosis and metabolic disease models. This guide distills recent mechanistic breakthroughs, actionable protocols, and troubleshooting strategies to maximize reproducibility and translational impact for cardiovascular research.
-
MLKL Polymerization Triggers Lysosomal Permeabilization in N
2026-07-28
This study uncovers how MLKL polymerization at the lysosomal membrane induces permeabilization, leading to cathepsin B release and driving necroptosis. The findings clarify the sequence and mechanism of lysosome-dependent cell death, providing new directions for targeting necroptosis in disease.
-
MLKL-Induced Lysosomal Permeabilization Drives Necroptosis
2026-07-27
This study reveals that polymerized MLKL targets lysosomal membranes, inducing permeabilization and the release of cathepsins—especially CTSB—thereby driving necroptosis. These findings establish lysosomal membrane permeabilization as a pivotal event in necroptotic cell death, highlighting new avenues for intervention in cell death pathways.